6 results
Primary Safety Objective: To describe the safety profile of 20vPnC
1. A better understanding of the apraglutide dose/concentration-effect relationship;2. A better understanding of duration of effect (apraglutide kinetics in relation to citrulline kinetics).
To assess the safety, tolerability, and efficacy of ABBV-154 administered every other week (eow) and every 4 weeks (e4w) subcutaneously (SC) vs placebo in subjects with moderately to severely active RA with inadequate response to at least one prior…
The purpose of this study is to see if the study compound, apraglutide, has any effect on the gastric emptying of liquids in healthy subjects. Gastric emptying is the normal way in which food passes through the body, when the contents of the stomach…
To assess the safety and efficacy of ABBV-154 versus placebo in subjects with PMR, who are dependent on treatment with glucocorticoids withdoses of at least 5 mg/day prednisone equivalent (glucocorticoindependent PMR).
The primary objective of the study is to assess the efficacy, safety, and tolerability of ABBV 154 in comparison with placebo in subjects with moderately to severely active CD who had inadequate response to or were intolerant of prior biologics.